Literature DB >> 22269311

Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma.

Danbi Lee1, Young-Hwa Chung, Jeong A Kim, Yoon Seon Lee, Don Lee, Myoung Kuk Jang, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Yung Sang Lee.   

Abstract

OBJECTIVES: The study was aimed to investigate the relationship between plasma transforming growth factor beta 1 (TGF-β(1)) expression and the characteristics of hepatocellular carcinoma (HCC).
METHODS: Five hundred and seventy-one patients with HCC were subjected. Plasma TGF-β(1) levels were measured by enzyme-linked immunosorbent assay at diagnosis and compared in accordance with clinical and radiological characteristics.
RESULTS: Plasma TGF-β(1) levels were significantly higher in the diffuse infiltrative type (n = 159) than in the nodular type of HCC (n = 412; 3.94 ± 0.34 vs. 3.79 ± 0.29 log(10) pg/ml; p < 0.001). They were much higher in patients with portal vein thrombosis or extrahepatic metastasis than in those without (3.88 ± 0.34 vs. 3.81 ± 0.29 log(10) pg/ml, p = 0.008; 3.94 ± 0.35 vs. 3.82 ± 0.30 log(10) pg/ml, p = 0.013, respectively). Also, plasma TGF-β(1) levels showed a positive correlation with the size of HCC (r = 0.014, p < 0.001). Additionally, plasma TGF-β(1) levels were inversely related to the survival periods (p < 0.001).
CONCLUSION: TGF-β(1) was overexpressed in invasive types of HCC and it may be involved in the rapid progression of HCC.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22269311     DOI: 10.1159/000335605

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  25 in total

Review 1.  Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma.

Authors:  Zhi-Hui Gao; Dou-Sheng Bai; Guo-Qing Jiang; Sheng-Jie Jin
Journal:  World J Hepatol       Date:  2015-01-27

2.  TGF-β1 pathway affects the protein expression of many signaling pathways, markers of liver cancer stem cells, cytokeratins, and TERT in liver cancer HepG2 cells.

Authors:  Xin-Hong Wang; Ming-Na Liu; Xun Sun; Chun-Huan Xu; Jing Liu; Jing Chen; Rui-Ling Xu; Bao-Xin Li
Journal:  Tumour Biol       Date:  2015-10-13

3.  TGF-β1 signaling pathway serves a role in HepG2 cell regulation by affecting the protein expression of PCNA, gankyrin, p115, XIAP and survivin.

Authors:  Xin-Hong Wang; Zhi-Guo Chen; Rui-Ling Xu; Cheng-Qian Lv; Jing Liu; Bing Du
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

Review 4.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

Review 5.  Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.

Authors:  Bruna Scaggiante; Maryam Kazemi; Gabriele Pozzato; Barbara Dapas; Rosella Farra; Mario Grassi; Fabrizio Zanconati; Gabriele Grassi
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

6.  MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-β1 autoregulation circuitry.

Authors:  Wei Yu; Changshan Huang; Qian Wang; Tao Huang; Yuechao Ding; Chao Ma; Hongbo Ma; Weiyu Chen
Journal:  Tumour Biol       Date:  2014-08-03

7.  Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.

Authors:  Ling Yang; Sayaka Inokuchi; Yoon Seok Roh; Jingyi Song; Rohit Loomba; Eek Joong Park; Ekihiro Seki
Journal:  Gastroenterology       Date:  2013-02-04       Impact factor: 22.682

8.  Comparative analysis of TGF-β/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines.

Authors:  Johanna Dzieran; Jasmin Fabian; Teng Feng; Cédric Coulouarn; Iryna Ilkavets; Anastasia Kyselova; Kai Breuhahn; Steven Dooley; Nadja M Meindl-Beinker
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

Review 9.  Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring.

Authors:  Li Wang; Min Yao; Zhizhen Dong; Yun Zhang; Dengfu Yao
Journal:  Tumour Biol       Date:  2013-09-05

10.  Targeted therapies in the treatment of advanced hepatocellular carcinoma.

Authors:  Zhengyu Wei; Cataldo Doria; Yuan Liu
Journal:  Clin Med Insights Oncol       Date:  2013-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.